Replicor Compassionate Access Program
- Conditions
- Viral Hepatitis BViral Hepatitis DCirrhosis, LiverDecompensated CirrhosisAscites HepaticVarices, EsophagealHepatocellular Carcinoma
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Replicor Inc.
- Registration Number
- NCT05683548
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇫🇷AP-HP Hôpital Beaujon, Clichy, France
🇫🇷CHU Lille, Lille, France
A Long Term Follow-up Study of Patients From the REP 301 Protocol
Completed
- Conditions
- Hepatitis D, ChronicHepatitis B, Chronic
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02876419
- Locations
- 🇲🇩
Infectious Clinical Hospital (n.a. Toma Ciorba), Chisinau, Moldova, Republic of
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02726789
Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02646163
- Locations
- 🇧🇩
Farabi General Hospital, Dhaka, Bangladesh
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02646189
- Locations
- 🇧🇩
Farabi General Hospital, Dhaka, Bangladesh
REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection
Phase 2
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02565719
- Locations
- 🇲🇩
Infectious Clinical Hospital (n.a. Toma Ciorba), Department 4, Chisinau, Moldova, Republic of
🇲🇩Repiblican Clinical Hospital (ARENSIA unit), Chisinau, Moldova, Republic of
🇲🇩Infectious Clinical Hospital (n.a. Toma Ciorba) Department 5, Chisinau, Moldova, Republic of
REP 2139-Ca / Pegasysâ„¢ Combination Therapy in Hepatitis B / Hepatitis D Co-infection
Phase 2
Completed
- Conditions
- Chronic HBV Infection (HBeAg Negative)
- Interventions
- Drug: REP 2139-Ca + Pegasys (TM)
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Replicor Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02233075
- Locations
- 🇲🇩
Infectious Clinical Hospital ( n.a. Toma Ciorba), Chisinau, Moldova, Republic of
© Copyright 2025. All Rights Reserved by MedPath